174 related articles for article (PubMed ID: 18598229)
1. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases.
Tumani H; Teunissen C; Süssmuth S; Otto M; Ludolph AC; Brettschneider J
Expert Rev Mol Diagn; 2008 Jul; 8(4):479-94. PubMed ID: 18598229
[TBL] [Abstract][Full Text] [Related]
2. [CSF biomarkers: proteomics investigations and clinical applications in neurodegenerative disorders].
Gabelle A; Roche S; Lehmann S
Rev Neurol (Paris); 2009 Mar; 165(3):213-22. PubMed ID: 18808768
[TBL] [Abstract][Full Text] [Related]
3. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases.
Otto M; Lewczuk P; Wiltfang J
Methods; 2008 Apr; 44(4):289-98. PubMed ID: 18374272
[TBL] [Abstract][Full Text] [Related]
4. Development of biomarkers for multiple sclerosis as a neurodegenerative disorder.
Ziemann U; Wahl M; Hattingen E; Tumani H
Prog Neurobiol; 2011 Dec; 95(4):670-85. PubMed ID: 21524682
[TBL] [Abstract][Full Text] [Related]
5. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.
Kuhle J; Regeniter A; Leppert D; Mehling M; Kappos L; Lindberg RL; Petzold A
J Neuroimmunol; 2010 Mar; 220(1-2):114-9. PubMed ID: 20117845
[TBL] [Abstract][Full Text] [Related]
6. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF).
Maurer MH
Mass Spectrom Rev; 2010; 29(1):17-28. PubMed ID: 19116946
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes.
Strekalova H; Buhmann C; Kleene R; Eggers C; Saffell J; Hemperly J; Weiller C; Müller-Thomsen T; Schachner M
Neurobiol Aging; 2006 Jan; 27(1):1-9. PubMed ID: 16298234
[TBL] [Abstract][Full Text] [Related]
8. Identification of brain cell death associated proteins in human post-mortem cerebrospinal fluid.
Burgess JA; Lescuyer P; Hainard A; Burkhard PR; Turck N; Michel P; Rossier JS; Reymond F; Hochstrasser DF; Sanchez JC
J Proteome Res; 2006 Jul; 5(7):1674-81. PubMed ID: 16823975
[TBL] [Abstract][Full Text] [Related]
9. CSF proteome: a protein repository for potential biomarker identification.
Romeo MJ; Espina V; Lowenthal M; Espina BH; Petricoin EF; Liotta LA
Expert Rev Proteomics; 2005 Jan; 2(1):57-70. PubMed ID: 15966853
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid biomarkers in neurological diseases in children.
Shahim P; Månsson JE; Darin N; Zetterberg H; Mattsson N
Eur J Paediatr Neurol; 2013 Jan; 17(1):7-13. PubMed ID: 23026858
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid biomarkers showing neurodegeneration in dogs with GM1 gangliosidosis: possible use for assessment of a therapeutic regimen.
Satoh H; Yamato O; Asano T; Yonemura M; Yamauchi T; Hasegawa D; Orima H; Arai T; Yamasaki M; Maede Y
Brain Res; 2007 Feb; 1133(1):200-8. PubMed ID: 17196562
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
[TBL] [Abstract][Full Text] [Related]
13. [Recent advances in pathogenesis and therapy of multiple sclerosis].
Linker RA; Stadelmann C; Diem R; Bähr M; Brück W; Gold R
Fortschr Neurol Psychiatr; 2005 Dec; 73(12):715-27. PubMed ID: 16355314
[TBL] [Abstract][Full Text] [Related]
14. Circulating microRNAs in the cerebrospinal fluid of patients with brain diseases.
Machida A; Ohkubo T; Yokota T
Methods Mol Biol; 2013; 1024():203-9. PubMed ID: 23719953
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin D2 synthase and its post-translational modifications in neurological disorders.
Lescuyer P; Gandini A; Burkhard PR; Hochstrasser DF; Sanchez JC
Electrophoresis; 2005 Dec; 26(23):4563-70. PubMed ID: 16259013
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-based dissection of neurodegenerative diseases.
Olsson B; Zetterberg H; Hampel H; Blennow K
Prog Neurobiol; 2011 Dec; 95(4):520-34. PubMed ID: 21524681
[TBL] [Abstract][Full Text] [Related]
17. Identification of glycoproteins in human cerebrospinal fluid.
Hwang HJ; Quinn T; Zhang J
Methods Mol Biol; 2009; 566():263-76. PubMed ID: 20058177
[TBL] [Abstract][Full Text] [Related]
18. Clinical proteomics in neurodegenerative disorders.
Zetterberg H; Rüetschi U; Portelius E; Brinkmalm G; Andreasson U; Blennow K; Brinkmalm A
Acta Neurol Scand; 2008 Jul; 118(1):1-11. PubMed ID: 18279484
[TBL] [Abstract][Full Text] [Related]
19. Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics.
Kroksveen AC; Opsahl JA; Aye TT; Ulvik RJ; Berven FS
J Proteomics; 2011 Apr; 74(4):371-88. PubMed ID: 21111852
[TBL] [Abstract][Full Text] [Related]
20. Increased mitochondrial oxidative damage and oxidative DNA damage contributes to the neurodegenerative process in sporadic amyotrophic lateral sclerosis.
Murata T; Ohtsuka C; Terayama Y
Free Radic Res; 2008 Mar; 42(3):221-5. PubMed ID: 18344116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
